![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, August 09, 2018 3:46:59 PM
I agree that the longer drop counts as 2 and sometimes as 3!
You indicated every step down with little red dots and i see 18 between 30 and 36 months.
The last one is at 36 months and a few days.That's the moment one of the 44 patients died.
The first red dot is not at 30 months but at the end of month 29.
Conclusion: speaking about that section between 30 and 36 months:
7 censored and i believe alive at the time of the analysis.
16 died.(67-44=23 and 16+7=23)
Your post 185633
I count 25 red dots on the section between 24 to 30 months.
That red dot at 30 months belongs to this section. So you have 25 + 1= 26 died.
We know from ASCO 2018 that 115 patients lived 24 months or more.
115- 67 (30 months)= 48 patients.
48 – 26(died) = 22 censored between 24 and 30 months and i believe alive at the time of the analysis.
let's find out how many patients had surgery before March 15, 2015.
(Marnix Bosch did not give us that number)
331-223 (at 30 months) = 108 patients between September 15, 2014 and August 15, 2015.(11 months) That is an average of 10/month.
223 + 60 = 283.
If i look at the Enrollment Timeline i see 87% enrolled June 15, 2015 (3 months after surgery)
https://www.nwbio.com/Boston-slides-31Aug2017-v0.5.pdf
87% of 331 = 288
take the average of 288 and 283 = 285
placebo= 95
treatment=190
So where are the 108 patients alive at the OS curve.(at the time of the analysis)
I guess that 3 died of the 44 patients who lived for at least 36 months. That’s 41 alive.(after the 36 month timeline)
Between 24 and 36 months: 22 + 7 = 29 alive.
Conclusion: 108 – 29 – 41 = 38 patients alive between 19 and 24 months.
38 patients of a group of 46. (331-285=46)
Placebo: 4 (99-95)
Treatment: 42 (46-4)
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM